No Detail Found!

Combination of anlotinib and second-line chemotherapy as surrogate to reduce immunosuppression in patients with advanced non-small cell lung cancer

Author(s)
Zhi Lou Department of Oncology, Lianyungang First People’s Hospital, Lianyungang, Jiangsu Province 222000, P.R. China.
Xin Wang Department of Oncology, Lianyungang First People’s Hospital, Lianyungang, Jiangsu Province 222000, P.R. China.
Chenxi Hu Department of Oncology precision laboratory, Lianyungang First People’s Hospital, Lianyungang, Jiangsu Province 222000, P.R. China.
Weixuan Liu Department of Oncology, Lianyungang First People’s Hospital, Lianyungang, Jiangsu Province 222000, P.R. China.
Yajun Ji Department of Oncology, Lianyungang First People’s Hospital, Lianyungang, Jiangsu Province 222000, P.R. China.
Abstract
Objective: To study the clinical efects of anlotinib combined with second-line chemotherapy (SLC) on immunosuppression in patients with advanced non-small cell lung cancer (NSCLC). Methods: In this retrospective study, the medical records of 106 patients with advanced NSCLC admitted to the Lianyungang First People's Hospital from November 2020 to March 2022 were retrospectively analyzed. Amongst 106 patients, 53 patients received second-line single-agent chemotherapy regimens (SLC group), and 53 patients received anlotinib combined with SLC (ASLC group). Prognosis, levels of immune cells and inflammatory cytokine, and adverse reactions were analyzed. Results: Clinical eficacy of the ASLC group was significantly higher than the SLC group (p0.05). After treatment, levels of tumor necrosis factor-a (TNF-a), interleukin-10 (IL-10), interleukin-8 (IL-8), interleukin-6 (IL-6) in the ASLC group were lower compared to the SLC group (p<0.05). Conclusion: In patients with advanced NSCLC, anlotinib combined with SLC is associated with higher levels of immune cells and reduced inflammatory factors. This treatment regimen, thus, can reduce immunosuppression and improve the prognosis of NSCLC patients.
Publication Details
Page(s) 1509-1515
Published Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 7, Year: 2024

Request the full text from PASTIC

Keywords
immunosuppression, Non-small Cell Lung Cancer, inflammatory cytokines, Anlotinib, Secondline chemotherapy, Immune cells
References
Bray F,Ferlay J,Soerjomataram I,Siegel RL,Torre LA,Jemal A .2018 .Global cancer statistics: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 10(6) : 394-424.
Xue C,Dong H,Chen Y,Lu X,Zheng S,Cui H .2022 .Neoadjuvant Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. J Coll Physicians Surg Pak, 06(6) : 779-788.
Jiao J,Li WW,Shang YH,Li XF,Jiao M. .2023 .Clinical effects of Chemotherapy combined with Immunotherapy in patients with advanced NSCLC and the effect on their nutritional status and immune function. Pak J Med Sci, 10(2) : 6365-408.
Ma G,Chen W .2019 .Effect of Docetaxel Combined with Cisplatin Preoperative Neoadjuvant Chemotherapy for Stage III NSCLC. J Coll Physicians Surg Pak, 12(12) : 1230-1231.
Xian-Jun F,Xiu-Guang Q,Li Z,Hui F,Wan-Ling W,Dong L .2014 .ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy. Pak J Med Sci, 10(3) : 488-492.
Langen DAJ,Johnson ML,Mazieres J,Dingemans AMC,Mountzios G,Pless M .2023 .Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. , 6736(23) : 00221-0.
Bottger F,Radonic T,Bahce I,Monkhorst K,Piersma SR,Pham TV . .Identification of protein biomarkers for prediction of response to platinum-based treatment regimens in patients with non-small cell lung cancer. Mol Oncol, 10 : 13555.
Liu B,Wang Y,Tian S,Hertzanu Y,Zhao X,Li Y .2020 .Salvage treatment of NSCLC recurrence after first-line chemotherapy failure: Iodine-125 seed brachytherapy or microwave ablation? Thorac Cancer. , 10(3) : 13320-7714.
Saltos AN,Creelan BC,Tanvetyanon T,Chiappori AA,Antonia SJ,Shafique MR .2023 .A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer, 10 : 107313.
.2022 .Health Commission Of The People's Republic Of China N. National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version). Chin J Cancer Res, 03(3) : 9604-206.
. .US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. , : 50.
Eisenhauer EA,Therasse P,Bogaerts J,Schwartz LH,Sargent D,Ford R .2008 .New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 10(2) : 228-247.
Wang HY,Chu JF,Zhao Y,Tang H,Wang LL,Zhou MQ .2020 .A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer. Cancer Manag Res, 10 : 3827-3834.
He Z,Yang X,Ma T,Yang Q,Zhang C,Chen Y .2022 .Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as ifrst-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced nonsquamous non-small cell lung cancer in China: a multicenter, single-arm trial. Transl Lung Cancer Res, 10(8) : 1657-1666.
Li SH,Li YW,Li YJ,Liu LB,Zhang Q,Lu D .2023 .A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors. Int J Gen Med, 10 : 4485-4498.
Saharinen P,Eklund L,Pulkki K,Bono P,Alitalo K. VEGF .2011 .and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med, 17(7) : 347-362.
Hicklin DJ,Ellis LM .2005 .Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 23(5) : 1011-1027.
Xu Y,Huang Z,Lu H,Yu X,Li Y,Li W .2019 .Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study. Br J Cancer, 10(8) : 640-646.
Zhao Y,Wan B,Zhang T,Xu Y,Liu H,Lv T .2019 .Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis. Transl Lung Cancer Res, 10(6) : 829-837.
Liu Y,Li HM,Wang R.,Effectiveness R. .2021 .Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A MetaAnalysis. Front Med (Lausanne), 10 : 616380.
Si X,Zhang L,Wang H,Zhang X,Wang M,Han B,Cancer Thorac .2019 .Management of anlotinib-related adverse events in patients with advanced nonsmall cell lung cancer: Experiences in ALTER-0303. , 10(3) : 12977-7714.
Han B,Li K,Wang Q,Zhang L,Shi J,Wang Z .2018 .Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol, 10(11) : 1569-1575.
Lin B,Song X,Yang D,Bai D,Yao Y,Lu N .2018 .Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. , 02 : 77-86.
Daum S,Hagen H,Naismith E,Wolf D,Pircher A .2020 .The Role of Anti-angiogenesis in the Treatment Landscape of Non-Small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel Inhibition. Front Cell Dev Biol, 10 : 610903.
Chen K,Xu Y,Huang Z,Yu X,Hong W,Li H .2023 .Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial. Cancer Med, 10(19) : 19460-19470.
Zou B,Jiang H,Liu H .2023 .Anlotinib Combined with Anti-PD1 Potentiates Anti-Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming. Adv Therap, 6(11) : 2300141.
Xie C,Wan X,Quan H,Zheng M,Fu L,Li Y .2018 .Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci, 10(4) : 1207-1219.
Abdalla AME,Xiao L,Ullah MW,Yu M,Ouyang C,Yang G .2018 .Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics. , 10(2) : 533-548.
Wu D,Nie J,Dai L,Hu W,Zhang J,Chen X .2019 .Salvage treatment with anlotinib for advanced non-small cell lung cancer. Thorac Cancer, 10(7) : 1759-7714.
0

Citations

0

Downloads

128

Views